How to improve manufacturing process efficiency to increase speed-to-market

whitePaper | July 13, 2023

Most medicines in development today target diseases affecting large sections of the global population. But now we are slowly beginning to see a rise in the interest of developing ”orphan drugs,” or pharmaceutical agents intended to treat rare diseases.

whitePaper | December 22, 2022

The life sciences industry has been exploring ways to accelerate the study start up process for well over a decade. The industry has long understood the value behind faster clinical trials: the sooner clinical trial results can be delivered to agencies, the sooner a new treatment can be available for patients.

whitePaper | May 18, 2022

Post-COVID conditions, also known by such terms as long COVID and post-acute sequelae of COVID-19, have become an issue of growing national concern.

whitePaper | February 28, 2022

Starting in Week 9 of 2020, prescription volume and claims data entered a period of intense volatility, followed by a steady state

whitePaper | December 22, 2022

According to research, post-pandemic R&D growth is healthy in the pharma industry with the number of drugs in the R&D pipeline now exceeding 20,000 in 2022—which represents an expansion rate of 8.22% from 2021 (1).

whitePaper | October 27, 2022

In today’s evolving, value-based environment for specialty drugs, hightouch services that enhance patient outcomes are playing an increasingly important role in market access and patient care delivery